Skip to main content

Psychedelics Business

Aion Therapeutic has announced the opening of the Aion International Center for Psychedelic Psychiatry, a Jamaica-based facility that will specialize in the use of psilocybin in treating addiction, depression, major depressive disorder, and other mental health conditions.
Ahead of a U.S. public offering, atai Life Sciences, a biopharmaceutical firm developing psychedelic and non-psychedelic compounds for mental health disorders, announced on Wednesday that it has closed a $157 million Series D round of financing.
Earlier this month, ATMA Journey Centers opened ATMA Calgary Urban Journey Clinic, the first non-ketamine psychedelic therapy clinic in Canada.
With the approval of psychedelic medicines imminent, the Psychiatry & Behavioral Health Learning Network (PBHLN) has announced that its inaugural Sana Symposium will take place Sept. 17-19, 2021.
Ronan Levy, co-founder and executive chairman of Field Trip Health, joins the BHE Podcast to discuss transitioning from practicing law to entrepreneurship endeavors that challenge the status quo, surging interest in the therapeutic potential of…
With the approval of psychedelic medicines imminent, the Psychiatry & Behavioral Health Learning Network (PBHLN) has announced that its inaugural Sana Symposium will take place Sept. 17-19, 2021.
Back to Top